FINAL
Press Release
Innovotech signs agreement for distribution of its bioFILM PA™ test in
Israel
Edmonton, Alberta, July 27, 2010 – Innovotech Inc. (TSX-V: IOT), a pioneer in the field
of biofilm product development, has signed an exclusive distribution agreement with
LevPharm Ltd of Israel to market and distribute its bioFILM PA™ test to hospitals and
clinics within Israel.
“We are very excited to enter into this agreement with LevPharm, who recognize the
significant impact the bioFILM PA™ test can have on improving patient care while
reducing the cost burden to health care systems,” said Ken Boutilier, President and CEO
of Innovotech Inc. “The partnership with LevPharm illustrates their understanding of the
importance of technologies for biofilm management, and further demonstrates Israel’s
leadership in embracing innovative products and solutions to enhance their health care
system.”
The current market capacity in Israel for acute infection treatment alone is estimated to
be over 3,000 bioFILM PA™ tests per year.
bioFILM PA™ is the first diagnostic test to assist physicians in the selection of the most
effective combination antibiotic treatment of patients with biofilm-based Pseudomonas
aeruginosa infections.
Pseudomonas aeruginosa is a common bacterium responsible for many hospital
acquired infections including ventilator-associated pneumonia and those found in
patients with burns and wounds. It is also one of the major causes of lung infections in
individuals with Cystic Fibrosis.
Over eighty percent of microbial infections in the body are caused by organisms in a
biofilm state. Biofilm infections are known to be up to 4,000 times more resistant to
antibiotics than the same organism in a free-floating state, which demonstrates why it is
so critical to identify effective treatments early, such as through the bioFILM PA™ test.
About Innovotech Inc.:
Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing
innovative and practical solutions to medical, agricultural and industrial problems caused by
microbial biofilms. Biofilms are responsible for a host of diseases both in agriculture and human
health due to their inherent resistance to existing antibiotics and disinfectants. There are
currently no antibiotics, disinfectants, diagnostics or regulatory standards designed specifically
for biofilm-forming organisms.
Innovotech currently has two products in advanced stages of development: Agress™ a unique,
environmentally friendly seed treatment and plant spray designed to protect crops against both
bacterial and fungal infections, and bioFILM PA™, the first diagnostic kit to assist physicians in
the selection of the most effective combination antibiotic treatment of patients with biofilm-based
chronic lung infections.
About LevPharm Ltd.
LevPharm Ltd. is a privately owned Israeli pharmaceutical company focusing on marketing and
distribution of pharmaceuticals and medical devices primarily in the area of pulmonary diseases.
Through their long experience in this market, the professionals at LevPharm focus on building
relationships with clinicians and institutions nation-wide. LevPharm currently represents
international pharmaceutical and medical device firms in Israel and is actively seeking to expand
this portfolio.
For more information contact:
Ken Boutilier, President and CEO
Innovotech Inc.
Phone: (780) 448-0585 ext. 221
Fax: (780) 424-0941
Email: ken.boutilier@innovotech.ca
Website: www.innovotech.ca
This document may contain forward-looking statements that are predictive in nature and subject to risks and
uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such
risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of
customers including government organizations; fluctuations in operating results; government policies or actions;
progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property
protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters
beyond the control of management. Should known or unknown risks or uncertainties materialize, or should
management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The
Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by
applicable law.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.